iHeart Japan Corporation

iHeart Japan Corporation is a Kyoto-based regenerative medicine company developing iPS cell-derived cardiac muscle sheet products to treat severe heart failure. Its lead product, ReHeart, consists of cardiomyocyte sheets differentiated from induced pluripotent stem cells and is designed to restore cardiac function in patients waiting for heart transplantation. The company, which has received J-Startup designation from the Japanese government, has conducted clinical trials and received Japanese regulatory approval, positioning it as a global pioneer in iPS cell-based cardiac regenerative therapy.